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Abstract: Since second generation pneumococcal conjugate vaccines 
(pCVs) targeting 10 and 13 serotypes became available in 2010, the number 
of national policy makers considering these vaccines has steadily increased. 
An important consideration for a national immunization program is the tim-
ing and number of doses—the schedule—that will best prevent disease in the 
population. Data on disease epidemiology and the efficacy or effectiveness of 
pCV schedules are typically considered when choosing a schedule. practical 
concerns, such as the existing vaccine schedule, and vaccine program perfor-
mance are also important. In low-income countries, pneumococcal disease 
and deaths typically peak well before the end of the first year of life, making 
a schedule that provides pCV doses early in life (eg, a 6-, 10- and 14-week 
schedule) potentially the best option. In other settings, a schedule including a 
booster dose may address disease that peaks in the second year of life or may 
be seen to enhance a schedule already in place. A large and growing body of 
evidence from immunogenicity studies, as well as clinical trials and observa-
tional studies of carriage, pneumonia and invasive disease, has been system-
atically reviewed; these data indicate that schedules of 3 or 4 doses all work 
well, and that the differences between these regimens are subtle, especially in 
a mature program in which coverage is high and indirect (herd) effects help 
enhance protection provided directly by a vaccine schedule. the recent World 
Health Organization policy statement on pCVs endorsed a schedule of 3 pri-
mary doses without a booster or, as a new alternative, 2 primary doses with a 
booster dose. While 1 schedule may be preferred in a particular setting based 
on local epidemiology or practical considerations, achieving high coverage 
with 3 doses is likely more important than the specific timing of doses.
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The first pneumococcal conjugate vaccine (pCV) was licensed and used as part of a national immunization program in 2000.1 Since 
2004, the number of countries adopting pCVs has steadily increased. 
Initially, most introductions occurred in high-income settings. the 
licensure of new conjugate vaccines including 10 (pCV10) and 13 
(pCV13) serotypes along with financing support beginning in 2009 
from the GAVI Alliance2 has meant that lower income countries 
are now introducing pCVs. Because of the important contribution 
of pneumococcal disease to illness and deaths in young children,3 
the increasing availability of these vaccines around the world holds 
promise for dramatically improving child health in all settings.
Health officials have used a variety of schedules as they 
worked to fit pCVs into their existing national immunization pro-
grams (Fig. 1). In the united States, the first country to use pCV in 
2000, pCV7 was licensed and introduced on a schedule that matched 
the schedule of other routine infant immunizations (3 primary doses 
at 2, 4, 6 and a booster at 12–15 months), and later pCV13 was 
licensed on that same “3+1” schedule.4 this schedule was supported 
by high efficacy demonstrated by 2 large uS-based clinical trials.5,6 
In 2007, the World Health Organization (WHO) recommended that 
pCV be included in the routine schedule of all countries and that 
pCV could be administered as 3 primary doses without a booster.7 
the 3+0 schedule was supported by clinical trial evidence from 
Africa and matched most expanded programme Immunization (epI) 
schedules.8 Other countries have since adopted pCVs on schedules of 
either 3 or 4 total doses; the WHO recently updated their pCV policy 
to support use of 3 doses as either 3+0 or 2+1 schedules.9
In general, policy makers consider disease epidemiology (ie, 
“Who is most affected?”), evidence of vaccine efficacy or effectiveness 
(ie, “What schedule will prevent the most disease or deaths?”) and prac-
tical concerns (ie, “What schedule fits best with our current immuniza-
tion program?”) when choosing a particular schedule. Here, we aim to 
synthesize data that are relevant for policy makers looking to introduce 
pCV or revise their pCV schedule. no single schedule is clearly optimal 
for every setting; each schedule offers both benefits and limitations and 
the relative importance of these should be considered. First, we review 
aspects of pneumococcal epidemiology, in particular the timing for 
acquisition of carriage and peaks of pneumococcal disease that a vacci-
nation program will aim to prevent. next, we summarize the knowledge 
about how well different schedules have been shown to reduce carriage 
and disease from our systematic review of pCV dosing reported in this 
supplement and other sources. Finally, we discuss practical considera-
tions for implementation that might impact schedule choice.
EPIDEMIOLOGY
While anyone can develop pneumococcal disease, disease 
most often strikes the vulnerable: infants, the elderly and persons of 
any age who have underlying medical conditions that might weaken 
their immune systems. persons with sickle cell disease or AIDS have 
disease rates up to 100 times than those seen in healthy persons of 
the same age. As reviewed later in this article, policy makers in some 
countries recommend a pCV schedule with 4 doses (eg, 3+1) for 
selected groups of children at highest risk of pneumococcal disease, 
while using a 3-dose schedule for the general population of children.
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In wealthy populations, nearly all deaths from pneumococ-
cal disease occur in the elderly.10 In low-income settings, however, 
pneumococcal disease also leads to death in a large number of 
young children. Worldwide, an estimated 541,000 deaths attrib-
uted to pneumococcal disease occurred in 2008 among children <5 
years of age, nearly all of these in low-income countries.11 the tim-
ing of disease onset in children also differs between low-income 
and high-income settings. In developing countries, most pneumo-
coccal disease and deaths among children <5 years of age occur 
in the first year of life, with a peak in disease incidence before 6 
months of age; in wealthy countries, disease peaks closer to 12 
months of age with about half of the episodes occurring by 18 
months (Fig. 2). this timing of disease and mortality is a critical 
factor in deciding on a vaccine schedule. Delaying doses in set-
tings with high mortality or high disease burden among children 
<1 year of age, even for a schedule that may confer advantages for 
disease prevention in the second year of life and later in childhood, 
means that the earliest doses are not delivered at the time when 
protection is most needed.
Recommended vaccination schedules differ somewhat in 
response to the disease epidemiology seen in different settings. the 
routine epI schedule recommended by the WHO and used in most 
low-income countries in Africa and Asia consists of 3 doses given 
at 6, 10 and 14 weeks of age; this schedule starts earlier and has 
shorter intervals between doses than what is often used in high-
income settings (eg, 2, 4 and 6 months for the primary series).9 
the relatively compressed epI schedule is designed to quickly 
build immunity in children whose disease risk begins very early 
in life. In some settings, the ages of actual vaccine administration 
are delayed from the intended schedule; if so, policy makers should 
take this delay into account before recommending a drawn-out dos-
ing schedule.
the serotypes predominantly causing pneumococcal dis-
ease also vary with age, disease syndrome and, to some degree, 
setting; serotype epidemiology may be a consideration for pCV 
schedule choice. Over 90 pneumococcal serotypes have been 
identified based on differences in carbohydrate structure of the 
capsule, and the number is growing as molecular methods to sero-
type strains are expanded.12 Fortunately, a relatively small number 
FIGURE 1. Countries routinely using PCVs by schedule.71,72 Note that 2 countries use >1 schedule:  Australia (3+0 and 3+1) 
and Canada (2+1 and 3+1).
FIGURE 2. Distribution of cases of invasive pneumococcal 
disease for children <5 years, by month of age for 
children in a developing country (South Africa) and in an 
industrialized country (United States) [Data are unpublished 
and from the Group for Enteric, Respiratory and Meningeal 
Disease Surveillance in South Africa (GERM-SA), courtesy 
of Anne Von Gottberg and the US Active Bacterial Core 
surveillance/Emerging Infections Program Network, 
courtesy of Matthew Moore.].
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of serotypes cause most disease among children <2 years of age 
worldwide. the first conjugate vaccine, pCV7, included the 7 
most common serotypes causing disease among children <2 years 
of age in the united States.10 A global systematic review showed 
that the serotypes in pCV7 caused at least 70% of infections 
among young children in north America, europe and Australia, 
but 50–60% among young children in Africa, Asia and latin 
America. new formulations, pCV10 and pCV13, are estimated 
to include at least 70% of disease-causing serotypes in all regions 
of the world.13
pCV10 and pCV13 provided substantially better serotype 
coverage in Africa, Asia and latin America than pCV7 because 
these vaccine formulations include serotypes 1 and 5. these sero-
types may appear in epidemics, causing a lot of disease in some 
years and little in others, and are more likely to be associated with 
pneumonia than other syndromes.14 Furthermore, children >2 
years and healthy adults remain at risk for disease caused by these 
serotypes, even though rates of disease for the common pediat-
ric serotypes (eg, 6B, 14) are generally lower in these age groups 
than in the youngest children14; as a result, the age distribution for 
serotypes 1 and 5 is shifted to older ages than the age distribution 
for the other serotypes commonly causing disease in infants and 
children. If prevention of disease caused by serotype 1 is a high 
priority for a pCV immunization program, a schedule that opti-
mizes immunogenicity for this serotype and is thought to provide 
an extended duration of direct protection should be considered. 
While no data definitively indicate which schedule is best at pre-
venting disease caused by serotype 1, it has been hypothesized that 
a schedule that includes a booster dose late in the first year or early 
in the second year of life might be needed, given the age distribu-
tion of cases.15
pneumococcal transmission dynamics may also be an impor-
tant consideration for immunization schedule choice. the ability of 
a pCV immunization program to prevent disease in a household 
and throughout a community by reducing spread of pneumococci 
from vaccinated children to nonvaccinated persons has been shown 
to be a powerful driver of the cost-effectiveness of the program.16 
While colonization with pneumococci is common in children up to 
age 5 years and beyond in some high transmission settings, coloni-
zation with serotypes contained in pCVs is less common in adults 
than children. In some but not all settings, this reduced risk of vac-
cine serotype colonization can be seen as children age from infancy 
through older childhood.17,18 Catch-up programs targeting toddlers 
have been used in addition to routine infant schedules to quickly 
reduce transmission of vaccine-type pneumococci in a community 
as well as prevent disease in an age group still at relatively high risk 
for disease.
PERFORMANCE OF DIFFERENT PCV SCHEDULES
A growing body of literature has evaluated different pCV 
schedules on specific outcomes, such as immunogenicity, inva-
sive pneumococcal disease, pneumonia or carriage. While a large 
number of studies have looked at how well a single vaccine sched-
ule works against no vaccination, relatively few were designed to 
compare the effects of various schedules in a head-to-head fash-
ion. most head-to-head studies of vaccine schedules evaluated 
pCV immunogenicity, and more studies have been published on 
immunogenicity of pCVs than other outcomes. In this section, we 
will synthesize what these studies tell us about pCV schedules, 
in particular evaluating the number and timing of doses in the 
primary series, what a booster dose may add and what we have 
learned from evaluations of full schedules. Finally, what little is 
available on performance in high-risk groups and duration of pro-
tection is reviewed.
Number and Timing of Doses in a Primary Series
more than 60 publications address the immune response to 
pCV7 or higher valency pCVs.19 In addition, 3 different groups have 
conducted systematic reviews of the effect of different pCV dosing 
schedules on immune response, including 2 meta-analyses of head-to-
head trials of different schedules20,21 and 1 analysis that used modeling 
to compare across studies.19 the 3 reviews all found that a primary 
series of 3 doses results in a better immune response than 2 doses 
for most serotypes, especially when measured right after the primary 
series, at about 6–7 months of age (table 1). the differences are larg-
est for serotypes 6B and 23F and relatively small for the other sero-
types evaluated. For example, in the meta-analysis by Scott et al,21 
which included 5 randomized-controlled, head-to-head trials of pCV 
schedules, the proportion of children achieving antibody levels ≥0.35 
µg/ml (the correlate predicting efficacy and used for licensure pur-
poses) for 3 primary doses was 21% higher compared with 2 primary 
doses for serotype 6B and 17% higher for serotype 23F, but no more 
than 7% higher for the other serotypes examined. When measured at 
about 1 year of age, before a booster dose was given, little difference 
has been seen in antibody concentrations in children who had received 
either 2 or 3 primary doses within the first 6 months of life.19,22,23
Studies of the effects of different pCV schedules on pneumo-
coccal colonization in general correlate with findings of immuno-
genicity studies, indicating that 3 primary doses reduce colonization 
better than 2 primary doses, at least when measured shortly after 
finishing the series. Results from these carriage studies are summa-
rized in a systematic review.24 the review identified 3 head-to-head 
clinical trials, conducted in Fiji, the Gambia and Israel, compar-
ing colonization after the primary series among children who had 
received 2 doses to colonization among children receiving a 3-dose 
series.25–28 In these studies, children who had received 3 primary 
doses had less colonization than those receiving 2 doses when meas-
ured a few months after completing the series. In Israel, the differ-
ence in colonization rates was driven by reductions in colonization 
with serotypes 6B and 6A in the group that had received 3 primary 
doses.25,26 the systematic review also identified 10 clinical trials of 
various pCV formulations that compared prevalence of coloniza-
tion in the first year of life following either a 2- or 3-dose primary 
series compared with no vaccination.24 In all except 1 study of an 
investigational product, both 2- and 3-dose primary series reduced 
colonization of vaccine types compared with no vaccination.
Only 1 study has attempted to directly look for a differ-
ence in effectiveness between schedules of 2 or 3 primary doses 
for preventing a clinical disease endpoint, finding that any differ-
ences may be short lived.29 In this study, the investigators evaluated 
the impact of 2 versus 3 primary pCV7 doses against incidence of 
lower respiratory tract infections in a general pediatric population 
in the united States. this propensity-score-matched case-cohort 
study found that children who received 3 primary doses had fewer 
hospitalizations for lower respiratory tract infections up to the time 
of receipt of a booster dose (9.5 admissions per 1000 children) than 
those who only received 2 primary doses (17.3 admissions per 1000 
children). no difference was seen in the number of hospitalizations 
after the booster dose. In addition, this difference in admissions 
was only seen among children born in 2002; the authors hypothe-
sized that by 2003, 3 years after introduction of pCV7, herd effects 
lessened the difference in risk between the 2 groups. A uS study 
conducted shortly after pCV7 introduction suggested that cases 
of invasive disease caused by serotype 6A were overrepresented 
among children who had received only 1 or 2 doses compared with 
those who had received 3 or 4 doses.30
In addition to the number of doses, the interval between doses 
in the primary series may be an important consideration. A trial by 
Goldblatt et al31 that evaluated timing between doses found that 
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an interval of 2 months resulted in significantly better immune 
responses compared with a 1-month interval when starting vacci-
nation at 2 months of age. In an analysis using multivariable mod-
eling that included results from 145 study arms from 63 different 
immunogenicity studies, IgG geometric mean concentrations were 
generally higher for schedules using a 2-month interval compared 
with 1-month interval, but the difference was not significant when 
controlling for other factors.32 the age at first dose did not appear 
to be an important predictor of immune response in this model, and 
even doses given at birth have been shown in a clinical trial to be 
immunogenic and prime for doses given later.33 these studies, taken 
together, suggest that if a 2-dose primary series is used in a pCV 
immunization program, an interval of 2 months rather than 1 month 
may help to maximize immune response to vaccination.
Use of a Booster Dose
A booster dose is a powerful addition to a pCV schedule, in 
particular in terms of measured immune response. Giving a dose 
at about 1 year of age to children who have received a primary 
series results in a vigorous antibody response for most serotypes, 
and while immune responses following the primary series differ 
between those who received 2 or 3 primary doses, such differences 
disappear following a booster dose. two systematic reviews have 
assessed antibody level concentrations after the booster dose.19,21 In 
these, children who received 3 primary doses had, compared with 
children who received 2 primary doses, significantly better immune 
responses after the booster dose only for serotype 6B (table 1); this 
was true whether measured by the proportion of children with anti-
body levels above the 0.35 µg/ml threshold for predicting efficacy21 
TABLE 1. Summary of Systematic Reviews Evaluating Immunogenicity After the Primary Series and Booster Dose 
for 2- and 3-dose Primary Series
Reference Analytic Method
Types of  
Studies Included
Outcome  
Measure
Serotypes Having Statistically Significantly Better Response for 
a 3-dose Primary Series Compared with 2 Doses, by Time  
of Measurement
1 Month After Primary Series 1 Month After Booster
Types Number of Studies
3 Doses 
Better* Types
Number of 
Studies
3 Doses  
Better
Scott et al.21 Meta-analysis Randomized- 
controlled 
trials
Proportion of 
subjects with 
ELISA ≥0.35 
µg/mL†
1 2 1 2
4 5 4 2
5 2 ✓ 5 2
6B 5 ✓ 6B 2 ✓
7F 2 7F 1
9V 5 9V 2
14 5 ✓ 14 2
18C 5 18C 2
19F 5 19F 2
23F 5 ✓ 23F 2
Ruckinger 
et al.20
Meta-analysis Self controlled‡ Proportion of 
subjects with 
ELISA ≥0.35 
µg/mL
1 3 ✓ Not evaluated
3 2
4 5 ✓
5 3 ✓
6A 2 ✓
6B 5 ✓
7F 3 ✓
9V 5 ✓
14 5
18C 5 ✓
19A 2
19F 5
23F 5 ✓
Randomized- 
controlled 
trials
Proportion of 
subjects with 
ELISA ≥0.35 
µg/mL
1 1 Not evaluated
4 4 ✓
5 1 ✓
6B 4 ✓
7F 1 ✓
9V 4 ✓
14 4 ✓
18C 4 ✓
19F 4
23F 4 ✓
Knoll et al. 19 Multivariable 
modeling
Randomized- 
controlled 
trials
Postprimary geo-
metric mean 
concentration
1 31 1 13
5 31 ✓ 5 11
6B 109 ✓ 6B 45 ✓
14 110 ✓ 14 45
19F 111 ✓ 19F 45
23F 109 ✓ 23F 45
*Note that none of the analyses showed a better response for the 2-dose primary series; if the 3-dose primary series is not indicated as being better than the 2-dose series, the 
study found no statistically significant difference between the 2 schedules.
†Cut-offs of ≥0.25 µg/mL rather than ≥0.35 µg/mL were used in studies using the GlaxoSmithKline assay.
‡ELISA results were compared for 1 period to another in the same children rather than a different control group of children.
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or by geometric mean antibody concentrations.19 In addition, a 
booster dose generally results in higher antibody concentrations 
than does a primary series, regardless of whether antibody concen-
trations are measured approximately 1 month after a booster would 
be given (eg, 13 months) or when comparing results 1 month after 
the booster to those 1 month after the primary series.19 Antibody 
levels following a third dose of vaccine are higher when those doses 
are given as a 2+1 schedule than when given as a 3+0 schedule.19
While the benefits of a booster dose are clear when looking 
at immunological endpoints, few studies have explored the addi-
tional benefits a booster dose might provide for reducing carriage 
or clinical disease caused by vaccine serotypes. the best informa-
tion comes from carriage studies, which suggest a benefit at least 
in the short term for a booster dose—but only if the primary series 
contained 2 doses rather than 3. In a study from Israel, differences 
in vaccine serotype colonization between those getting 2 primary 
doses compared with 3 primary doses (ie, measured after the pri-
mary series) were no longer seen after children in both the 2-dose 
and 3-dose arms received a booster dose with pCV7.25,34 Of note, 
the study in Israel found that among those receiving a 3-dose pri-
mary schedule, there was no additional impact of a booster dose 
for further reducing Vt colonization.26 Another clinical trial, con-
ducted in the netherlands, demonstrated that a booster dose added 
to a 2-dose primary schedule increased the reduction in vaccine 
serotype colonization.35 In that study, children who received pCV7 
at 2 and 4 months (2+0) were compared to those getting doses at 
2, 4 and 11 months (2+1) and unvaccinated controls. At 12, 18 and 
24 months of age, children in both the 2+0 and 2+1 groups had 
significantly less vaccine-type carriage than unvaccinated controls. 
Children in the 2+1 group also had a significantly lower prevalence 
of vaccine-type carriage at 18 months (16%) than the 2+0 group 
(24%, P = 0.01); no difference was found at 24 months.
taken together, these head-to-head studies of the effect 
of different schedules on colonization show that 3 primary doses 
reduce colonization for some serotypes (eg, 6B) better than 2 pri-
mary doses up until the time of a booster dose and that a booster 
dose provides additional protection against vaccine serotype car-
riage but only for children who have received a 2-dose primary 
series and not for children who already received 3 doses. these 
findings agree with the observational study discussed earlier 
of lower respiratory tract infections, which indicated that after a 
booster dose, no difference was found in hospitalizations for lower 
respiratory tract infections for children who had received either 2 
or 3 primary doses.29 these findings, however, are inconsistent with 
the 1 study of invasive disease that assessed whether a booster dose 
provided additional benefit; in this case-control study, a schedule 
of 3 primary doses plus a booster was significantly more effective 
than 3 primary doses alone.36 Overall, booster doses are clearly 
beneficial for programs that use only 2 primary doses, but the clini-
cal benefit of a booster dose remains uncertain for programs that 
achieve high coverage with 3 primary doses.
Evaluations of Complete Schedules (2+1, 3+0 
and 3+1)
While examining the effects of the primary series and booster 
dose separately is useful for understanding differences between the 
biologic effects of various schedules, policy makers generally want 
to review the evidence in support of a complete schedule when 
making vaccine recommendations. the 3+1 schedule has more pub-
lished evidence documenting its efficacy and effectiveness than the 
other schedules (table 2), primarily because pCV7 was first used 
in the united States, a country that uses a 3+1 schedule. However, 
the body of evidence from clinical trials and observational studies 
supporting 3+0 and 2+1 schedules continues to grow. At this point, 
clinical trials have studied the 3+0 schedule more thoroughly than 
the 2+1 schedule, but more observational data are available for the 
2+1 schedule than the 3+0 schedule. With few exceptions, stud-
ies show that all of these schedules are protective against carriage, 
pneumonia and invasive disease. unfortunately, the different study 
methods do not readily allow direct comparison of the efficacy or 
effectiveness of 1 schedule to another.
Clinical trials using pCV7 were conducted in the united 
States and assessed a 3+1 schedule, with doses at 2, 4, 6 and 12–15 
months.5,6 efficacy against invasive disease in these 2 prelicen-
sure clinical trials ranged from 83% to 94%. the similar 9-valent 
vaccine formulation was evaluated in South Africa and the  Gambia 
using 3+0 schedules with doses given at 6, 10 and 14 weeks; effi-
cacy against invasive disease in these studies ranged from 71% 
to 83% among the general population of children and was a little 
lower (65%) among children with HIV in South Africa.8,37 While 
reports of clinical trials for 3+1 and 3+0 schedules were published 
between 2000 and 2005, the first randomized trial demonstrating 
efficacy for the 2+1 schedule was not published until 2012. this 
cluster-randomized trial in Finland38 evaluated both 2+1 schedule 
and 3+1 schedule for pCV10; the 2 schedules were each compared 
to a control group that received hepatitis B vaccine. Compared with 
12 cases of vaccine-type invasive disease that occurred in the con-
trol group, no cases occurred among children receiving the 3+1 
schedule (vaccine effectiveness 100%, 95% confidence interval 
(CI): 83–100%) and only 1 case occurred among children receiving 
TABLE 2. Number of Studies in Young Children Evaluating PCV Efficacy, Effectiveness or 
Impact After Vaccine Introduction by Outcome, Study Design and Schedule; Studies Using PPV23 
Booster Doses are Not Included24,43,45
Outcome Study Design
Number of Published Studies
2 + 1 3 + 0 3 + 1
Nasopharyngeal carriage
Randomized trials 2 4 5
Surveillance (before/after introduction) 2 0 8
Pneumonia
Randomized trials 0 5 4
Nonrandomized cohort 1 0 1
Surveillance (before/after introduction) 5 2 24
Invasive disease
Randomized trials 1 2 2
Surveillance (before/after introduction) 6 2 18
Case-control 2 1 2
Indirect cohort 0 3 3
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the 2+1 schedule (vaccine effectiveness 92%, 95% CI: 58–100%). 
note that even in the control arm, no children <1 year of age devel-
oped invasive disease, suggesting little opportunity to evaluate the 
potential for breakthrough disease before the booster dose in the 
2+1 arm and emphasizing the low disease risk in this population.
Similar to the literature on invasive disease, clinical trials 
evaluating pneumonia prevention using different pCV schedules 
show that 3+0, 2+1 and 3+1 schedules all provide some protec-
tion. Randomized clinical trials of 3+0 schedules from the phil-
ippines, South Africa and the Gambia have found reductions of 
23–37% for chest X-ray confirmed pneumonia among vaccinated 
children.8,37,39 In the united States, efficacy of a 3+1 schedule for 
pCV7 was 30% among children in northern California40 although 
efficacy was not demonstrated for hospitalized pneumonia episodes 
in a cluster-randomized trial among navajo children.41 preliminary 
data for pCV10 from latin America suggest good efficacy for the 
3+1 schedule (23%).42 A systematic review identified several trials 
that used clinical diagnosis of pneumonia rather than X-ray con-
firmed pneumonia for both 3+0 and 3+1 schedules; results for this 
less-specific endpoint were mixed.43 Only 1 nonrandomized cohort 
study has evaluated efficacy of a 2+1 schedule, finding 65% (95% 
CI: 47–78%) less X-ray confirmed pneumonia among children 
whose parents chose pCV compared with unvaccinated children.44
Observational studies conducted in settings where pCVs 
are routinely used also demonstrated pCV effectiveness against 
vaccine-type invasive disease and pneumonia for the 3- and 4-dose 
schedules. A systematic review of invasive disease studies identi-
fied 3 case-control studies and 3 indirect cohort analyses that evalu-
ated pCV7 effectiveness (table 2).45 Five of 6 studies were done 
in settings using 3+1 schedules, although most of the studies were 
able to include information on children with incomplete schedules 
and evaluate effectiveness for schedules with fewer doses. effec-
tiveness estimates for schedules using 3 or more doses (76–100%) 
were similar to efficacy measured in clinical trials evaluating an 
invasive disease endpoint.
Surveillance studies have also shown benefits of pCV by 
documenting drops in disease rates or reported cases of invasive dis-
ease and pneumonia following pCV introduction (table 2). In gen-
eral, these studies show disease reductions at least as good as those 
demonstrated in clinical trials and results are often better because 
of indirect effects. A systematic review identified 26 such studies of 
invasive disease.45 In nearly all studies regardless of schedule, rates 
of vaccine-type invasive disease dropped quickly after vaccine intro-
duction. While few data are available from developing countries, 
preliminary data from Kilifi, Kenya indicate promising reductions 
in invasive disease using 3 doses at 6, 10 and 14 weeks with catch-up 
provided for children up to age 5 years.46 to date, 33 surveillance-
type studies have assessed a pneumonia or empyema endpoint after 
introduction into a routine immunization schedule.43 While results 
of surveillance studies of pneumonia endpoints are less consistent 
than those evaluating invasive disease, in general, the findings sug-
gest 2+1, 3+0 and 3+1 schedules are all effective.
High-risk Populations
Children with chronic illnesses such as HIV or sickle cell 
disease can have disease rates >20 times than those seen in healthy 
children.1 While pCVs have been shown to provide protection for 
children with HIV,8 sickle cell disease47 and chronic illnesses as 
a group,36 some evidence suggests that pCVs may be somewhat 
less effective in children with chronic illnesses than in healthy 
children. In a large randomized-controlled clinical trial in South 
Africa, pCV9 used on a 3+0 schedule was shown to be efficacious 
against invasive pneumococcal disease caused by vaccine serotypes 
in both children with HIV and healthy children, although the point 
estimates were lower for HIV-infected children (65% vs. 83%).8 
For the endpoint of radiographically confirmed pneumonia, point 
estimates of efficacy were 13% and 20% for HIV-infected and unin-
fected children, respectively, and the estimate was only statistically 
significant for HIV-uninfected children. In a case-control evalua-
tion that was conducted in the united States, vaccine effectiveness 
for pCV7 serotypes was significantly lower among children with 
any chronic illness (as a group) than in healthy children (81% vs. 
96%).36 the recommended schedule in the united States was 3 pri-
mary doses plus a booster, although at the time of the study many 
children were missing doses because of a national shortage.
In Australia and north America, some populations of indig-
enous children have documented rates of pneumococcal disease up 
to 20 times higher than nonindigenous children.48–51 pCV7 has been 
shown to be effective in these groups. efficacy among the navajo 
and Apache in the united States in a community–randomized-con-
trolled clinical trial evaluating a 4-dose schedule of pCV7 was 82.6% 
against invasive disease,6 and invasive disease rates, nasopharyn-
geal carriage and pneumococcal transmission to adults decreased 
among navajo and Alaska natives after routine vaccination with 
pCV7 began.52,53 In Australia, where a schedule of 3 primary doses 
of pCV7 was used with a booster of 23-valent pneumococcal poly-
saccharide vaccine (ppV23), vaccination did not reduce pneumonia 
rates among aboriginal children in the northern territories.54
Whether using a schedule of 4 pCV doses will provide better 
protection than a schedule with 3 doses has not been evaluated for 
aboriginal children or for children with chronic illnesses. In spite 
of the lack of evidence, policy makers in some, but not all, coun-
tries that recommend either 3+0 or 2+1 schedules for the general 
population of children recommend 4-dose schedules for aboriginal 
or chronically ill children because of the higher risk of severe dis-
ease and complications compared with healthy children as well as 
concern over poor vaccine response.55 While a schedule consisting 
of 3 primary doses of pCV and a booster dose of ppV23 may seem 
attractive for high-risk children because of the potential for pre-
venting more serotypes, this schedule should be avoided because of 
the lack of effectiveness in aboriginal children in Australia54 and the 
potential for inducing hyporesponsiveness.56
Duration of Protection
Ideally, a pCV schedule should provide long-term protec-
tion through at least the period of childhood during which disease 
burden is significant. to date, however, few studies have attempted 
to assess the duration of protection that pCV provides. the best 
information comes from South Africa, where investigators contin-
ued to follow subjects from the randomized clinical trial to assess 
duration of efficacy of pCV9.57 In this population, where pCV9 was 
given at 6, 10 and 14 weeks without a booster dose, efficacy against 
invasive disease caused by vaccine serotypes was similar at 6.2 
years of follow-up (78%) compared with 2.3 years (83%) for HIV-
uninfected children, but efficacy fell among HIV infected [65% at 
2.3 years vs. 39% (95% CI: −7.8% to 65%) at 6.2 years]. the evi-
dence from South Africa provides some reassurance that a schedule 
without a booster can provide long-term protection against disease, 
at least in healthy children. However, because of the reduction in 
effectiveness over time among HIV-infected children, policy mak-
ers in South Africa adopted a novel 3-dose schedule (doses at 6 and 
14 weeks and 9 months), putting the last dose late in the first year of 
life in an attempt to improve longer term protection for these HIV-
infected children.56 more recently, South Africa recommended a 
3+1 schedule for HIV-infected children, as data from a  case-control 
study suggested the 2-dose primary series was not adequately pro-
tective (C. Cohen et al, unpublished data).
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Concern over duration of protection of a 3-dose primary 
series without a booster comes in part from experience with Haemo-
philus influenzae type b (Hib) vaccine. In the united Kingdom, Hib 
vaccine was introduced on a 3+0 schedule with catch-up vaccination 
for all children <5 years of age, resulting in dramatic reductions in 
disease. However, several years into the program, the rate of Hib 
meningitis among older children and adults began to rise, likely as a 
result of a complex interplay between reductions in population level 
Hib colonization, lower immunogenicity of Hib in combination vac-
cines that included acellular instead of whole cell pertussis antigens 
and the Hib dosing regimen; in response, a booster dose was added 
to the schedule and rates subsequently decreased.59 In the united 
States, where pCV7 has been used on a 4-dose schedule (2, 4, 6 and 
12–15 months) since 2000, no increase in disease caused by vaccine 
serotypes has been noted in older children through 2012.60
Duration of protection might be more of a concern for sero-
type 1 than for other pCV types, both because of the serotype’s ten-
dency to cause more disease in older children and adults and because 
some data suggest that any protection provided by a primary series 
of this vaccine antigen may be short lived. In an analysis combining 
data from the clinical trials in South Africa and the Gambia, both 
of which used pCV9 at 6, 10 and 14 weeks, investigators found that 
pCV9 did not provide significant protection against serotype 1 inva-
sive disease.15 Serotype 1 cases that occurred in the pCV9 group all 
occurred after 12 months of age, whereas several cases of serotype 
1 disease occurred before 12 months of age in the control arms. 
While the authors of this study speculated that a booster dose may 
be needed for control of serotype 1 disease, results from ongoing 
surveillance studies in the united Kingdom and Kenya, expected 
soon, should provide more definitive information.
PRACTICAL CONSIDERATIONS
practical considerations about effectively delivering pCV as 
part of a national program, such as cost and coverage, are often 
as important as scientific considerations like disease epidemiol-
ogy, vaccine safety and the vaccine’s likely benefits against dis-
ease. the licensed schedule is 1 such practical consideration. As 
new vaccines become available, data supporting their safety and 
efficacy are carefully considered by licensing bodies before the 
vaccines can be sold. the data reviewed may be from studies that 
used 1 particular schedule or may include studies using a variety of 
schedules, and the license granted may be limited to the data that 
was presented to the agency for review. the schedule used in the 
license is often what is adopted by policy makers. For example, in 
the united States, the Food and Drug Administration only reviewed 
data for pCV7 and pCV13 from studies that used schedules of 3 
primary doses given at 2, 4 and 6 months followed by a booster at 
12–15 months.61 Because these vaccines were then licensed in the 
united States on this schedule, uS vaccine policy as directed by 
the Centers for Disease Control and prevention’s Advisory Com-
mittee on Immunization practices recommended this schedule for 
pCV administration.4 elsewhere, policy makers may decide to use 
a schedule different than the licensed schedule or vaccine licenses 
may provide flexibility. In europe, the european medicines Agency 
has licensed both pCV10 and pCV13 with labels that provide the 
option of using either a 3+1 schedule or a 2+1 schedule, if the latter 
schedule is used as part of a routine immunization program.62,63 the 
WHO has “prequalified” both pCV10 and pCV13, performing a 
review similar to that done for licensing purposes. prequalification 
allows purchase of these vaccines by unICeF and other united 
nations agencies. the package inserts used for pCVs purchased 
by unICeF specify use of either a 3+1 or 2+1 schedule but also 
recommend taking into account local vaccination policy when 
determining the schedule.64 this latter language allows flexibility 
for pCV to be given on a 3+0 schedule, if that is the local policy, 
and still be in accordance with labeling.
Another important driver for choice of pCV schedule is the 
schedule already in use for other vaccines. Clinical trials demonstrated 
efficacy of pCVs when given along with other routine infant vaccines, 
and pCVs are licensed to be administered concomitantly with other 
vaccines. providing pCV at the same healthcare visit as other routine 
vaccines is often easier for both parents and immunization providers 
than requiring separate visits, and consolidating vaccinations into the 
fewest number of visits improves immunization coverage rates.65
Conversely, the choice of schedule could affect the immuni-
zation coverage rates ultimately achieved for pCV. In some settings, 
vaccine doses given early in infancy have higher uptake than doses 
given later. For example, in Burkina Faso, coverage for a measles-
containing vaccine (scheduled for administration at 9 months of age) 
in 2011 as reported by the WHO was only 63%, but coverage for the 
third dose of diphtheria-tetanus-pertussis (Dtp3) vaccine (scheduled 
for 14 weeks of age) was 91%.66 the difference in coverage rates 
suggest that compliance is worse for vaccination visits later in the 
first year of life compared with earlier visits. In settings where cover-
age for later doses is significantly lower than for earlier doses, a 3+0 
schedule is a better choice than a schedule requiring a booster dose.
Cost is also a practical consideration for policy makers, 
especially for those deciding between 3-dose and 4-dose schedules. 
Our review of the literature on pCV dosing schedules found only 
small differences in protection between 3- and 4-dose schedules, 
in particular for schedules using a 2-dose primary series compared 
with those using 3 primary doses in the months before the booster 
dose; those differences may not result in measurably different 
reductions in disease burden especially in settings where vaccine 
coverage is high enough for herd effects to provide additional pro-
tection. Cost-effectiveness analyses from the netherlands and the 
united States suggest that a 3+1 series was not cost-effective com-
pared with a 2+1 series, assuming that vaccine price was the same 
for the 2 schedules67 (CDC unpublished data). note that while a 
2-dose infant schedule has been proposed as potentially a better use 
of resources than a 3-dose series in low-income settings,68 a 2-dose 
infant schedule has not been tested in a clinical trial nor recom-
mended routinely in any country because of concerns that it may be 
significantly less effective than 3- or 4-dose schedules.
many policy makers who have introduced pCVs have done 
so using a catch-up campaign in their countries rather than restrict-
ing pCV to only those children born after the initiation of the pCV 
program. One objective of catch-up campaigns is usually to pro-
vide direct protection to infants and children targeted to receive the 
catch-up doses. the ability to conduct a catch-up vaccination pro-
gram and the age group included in the program depends on local 
epidemiology and available vaccine supply and resources. When 
pCV7 was first introduced in the united States, vaccination was rec-
ommended for all children <2 years of age and a subset of children 
at higher risk of disease (eg, those with certain medical conditions), 
who were 2–4 years of age.1 the recommendation was based on 
the high rates of pneumococcal disease among children <2 years of 
age (Fig. 2). In other settings where disease peaks well before age 
1 (see South Africa data in Fig. 2), a catch-up program limited to 
children <1 year of age would quickly protect those in the highest 
risk group, although the absolute risk of children beyond 1 year of 
age may still be important, especially relative to that risk in more 
developed countries. Others have provided vaccination to toddlers 
and older children < 5 years of age, not only to protect them but also 
to quickly produce “herd protection” by reducing transmission of 
vaccine serotype pneumococci in the community. In Kilifi, Kenya, 
2 doses of pCV10 were offered to all children <5 years of age in 
addition to the primary schedule of 3 doses given at 6, 10 and 14 
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weeks, and early results from an intensive surveillance program sug-
gest a rapid reduction in disease rates following vaccine implemen-
tation.46 While introduction of pCV for infants along with a catch-up 
program for older children may protect a population more quickly 
than introduction without a catch-up program, the added benefit that 
a catch-up program provides has not been directly measured. An 
assessment of catch-up policies is underway and will evaluate dis-
ease reduction, cost-effectiveness and financing of such programs.
How to best change from 1 vaccine formulation to another 
has become a question. Since licensure of pCV10 and pCV13, 
programs that began with pCV7 are now switching to these newer 
formulations, and policy makers question whether children who 
started their series with 1 vaccine can finish with another. Only a 
few studies have evaluated schedules comprised of >1 pneumococ-
cal vaccine. Schedules using all pCV7 doses and those starting 
with pCV7 and finishing with pCV13 (products made by the same 
manufacturer, pfizer, and using the same carrier protein, CRm197) 
result in comparable antibody levels for the 7 serotypes in common 
between the 2 vaccines, but somewhat lower antibody levels for the 
6 additional serotypes in pCV13.4 In the 1 study in which children 
received 3 primary doses with pCV7 and were then boosted with 
either pCV7 or pCV10 (a product made by a different manufac-
turer using a different carrier protein), antibody levels were higher 
for children receiving all pCV7 doses, especially for serotypes 6B 
and 23F, although functional activities measured by opsonophago-
cytic assays were similar.69 In practice, programs that were using 
pCV7 often simply have children receive pCV13 or pCV10 at their 
next scheduled dose. programs that switched from pCV7 to pCV10 
and use a schedule with a booster dose have sometimes opted to use 
pCV7 to complete the primary series and boost with pCV10.
ppV23 has been used in the past as a booster dose in some 
research studies and routinely among aboriginal children in Aus-
tralia, but this practice is no longer recommended in any setting, to 
our knowledge. In Australia, the ppV23 booster did not seem to help 
with disease prevention.54 In a trial in Fiji, use of ppV23 as a booster 
dose at 12 months of age in children who had received a primary 
series with pCV7 resulted in good antibody responses 1 month after 
the booster dose, but responses were significantly blunted to a partial 
dose of ppV23 given at age 18 months compared with children who 
had not received ppV23 at 12 months, suggesting that use of ppV23 
in this age group could result in immune hyporesponsiveness.56,70
CONCLUSION
With the increasing supply of 10- and 13-valent vaccines 
and financing as well as programmatic support from the GAVI 
Alliance, a large number of low-income countries are introducing 
pCV into their routine immunization schedules. Introducing pCV 
into an existing national immunization program can be complicated 
because of resource concerns and the need to expand the cold chain 
and other delivery resources. Choosing the optimal schedule, how-
ever, can be straightforward in many settings, especially if the 3- 
or 4-dose schedule in place for other routine infant immunizations 
can accommodate an additional vaccine and the epidemiology of 
disease will be addressed by the proposed timing of doses. As sum-
marized earlier, the literature on pCV schedules has identified few 
differences between 3- and 4-dose schedules, and a large body of 
evidence suggests that 3+0, 2+1 and 3+1 schedules are all highly 
effective compared with no vaccination. the differences that do 
exist between schedules are likely only relevant early in the course 
of a pCV program; once coverage is sufficient to induce herd effects 
such differences would likely be minimized and difficult to measure.
the WHO’s recent guidance on pCV now allows for flex-
ibility in the timing of doses. In October 2011, the WHO pulled 
together a meeting of epidemiologists, immunologists and other 
experts in the field to review and discuss available evidence support-
ing use of different vaccination schedules for pCV. the information 
was later summarized and presented to WHO’s Strategic Advisory 
Group of experts (SAGe), an international group of vaccine experts 
who assist WHO with vaccine policy formation. After this review, 
WHO published updated SAGe recommendations for pCV10 and 
pCV13 that replaced an earlier statement on pCV7. the new state-
ment, in addition to again recommending a schedule of 3 primary 
doses, recommended as an alternate schedule 2 primary doses plus 
a booster at around 1 year of age (table 3).9 According to the state-
ment, giving 3 primary doses may be preferred in settings in which 
disease rates peak well before the end of the first year of life or in 
which coverage is low for vaccines given late in the first year (eg, 
measles vaccine); use of a 2+1 schedule may be preferred in settings 
in which duration of protection may be a concern, especially for 
ongoing protection against serotype 1, but whether such a schedule 
provides longer protection than a 3+0 schedule has not been proven.
Some questions about vaccine schedules remain. In par-
ticular, some antigens in the new conjugate formulations, such as 
those targeting serotypes 1, 3 and 5, may prevent disease better 
in schedules using a booster dose; compared with other serotypes 
targeted by the vaccine, disease caused by these serotypes often 
occurs among older children. Whether the duration of protection 
is improved by added a booster dose, however, is unclear. In addi-
tion, the benefit of catch-up vaccination programs, compared with 
programs solely providing pCV to infants, has also not been meas-
ured. While these and other questions remain about how to fully 
optimize a pCV schedule, a large and growing body of evidence 
indicates that currently available pCVs are highly effective on a 
TABLE 3. Summary of 2012 WHO SAGE Recommendations for Use of PCV10 and PCV139
PCV recommended for childhood immunization schedules worldwide, particularly in high mortality settings.
Choice of PCV (PCV10 or PCV13) depends of factors such as prevalent serotypes, vaccine presentation and supply.
Primary immunization should be completed with same product; if not possible, series may be completed with other PCV.
Recommended schedules:
3 primary doses Alternative: 2 primary doses plus booster
Timing May begin at 6 weeks of age May begin at 6 weeks of age; booster between 9 and 
15 months
Minimum interval 4 weeks 8 weeks
Considerations May be preferred if disease incidence peaks <32 weeks of age
Preferred if coverage poor for vaccines given near 1 year of age 
(eg, measles)
Differences might be negligible with herd protection
High antibody level from booster dose may be 
important for certain serotypes (eg, serotype 1) or 
duration of protection
High-risk groups HIV-infected and preterm infants may benefit from booster dose 
in second year of life
Catch-up vaccination along with infant program will accelerate herd protection and vaccine benefits. Schedule: 2 doses at least 2 months apart for 
 children 12–23 months and 2–5 years of age with high-risk conditions
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range of schedules, allowing flexibility for policy makers to incor-
porate pCV into existing vaccination programs.
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